<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916032</url>
  </required_header>
  <id_info>
    <org_study_id>060801</org_study_id>
    <nct_id>NCT00916032</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A</brief_title>
  <official_title>Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to compare the pharmacokinetic parameters of 3000 IU
      Advate using one 3000 IU potency vial dissolved in 5 mL diluent with that of 3000 IU Advate
      using two vials of 1500 IU potency dissolved in 5 mL diluent each (administered in 10 mL
      diluent in total) in previously treated patients with severe hemophilia A (factor VIII level
      &lt; 1%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Computed using the linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). One-stage Activated Partial Thromboplastin Time (aPTT) Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Computed using the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery at Cmax - Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours.</time_frame>
    <description>Determined as the highest Factor VIII (FVIII) activity achieved post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery at Cmax - One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours.</time_frame>
    <description>Determined as the highest FVIII activity achieved post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery at 30 Minutes- Chromogenic Assay</measure>
    <time_frame>30 minutes pre-infusion and 30 minutes post-infusion</time_frame>
    <description>Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery at 30 Minutes- One-stage aPTT Assay</measure>
    <time_frame>30 minutes pre-infusion and 30 minutes post-infusion</time_frame>
    <description>Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Phase Half-life- Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Phase Half-life- One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII Clearance- Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>computed as the dose divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII Clearance- One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Computed as the dose divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)- Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)- One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State- Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>computed as Clearance (CL) * Mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State- One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>computed as CL * MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- Chromogenic Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Determined as the highest FVIII activity achieved post-infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- One-stage aPTT Assay</measure>
    <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
    <description>Determined as the highest FVIII activity achieved post-infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]</intervention_name>
    <description>Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ADVATE</other_name>
    <other_name>Antihemophilic Factor (Recombinant)- Plasma/albumin free method (rAHF-PFM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is 18 to 65 years old, at the time of screening

          -  Participant has provided signed informed consent

          -  Participant has severe hemophilia A, defined by a baseline FVIII level &lt; 1% of normal,
             as tested at screening at the central laboratory

          -  Participant's weight is between 55-65 kg

          -  Participant was previously treated with FVIII concentrate(s) for a minimum of 150
             exposure days prior to study entry

          -  If Participant is HIV positive, he must be immunocompetent as determined with a CD4
             count ≥ 200 cells/mm³ (CD4 count at screening)

          -  Participant is willing and able to comply with the requirements of the protocol

        Exclusion Criteria:

          -  Participant has a detectable FVIII inhibitor at screening, with a titer ≥ 0.4 Bethesda
             unit (BU) (Nijmegen modification of the Bethesda Assay) measured at the central
             laboratory

          -  Participant has a history of FVIII inhibitors with a titer ≥ 0.4 BU (by Nijmegen
             assay) or ≥ 0.5 BU (by Bethesda Assay) at any time prior to screening

          -  Participant has undergone a surgery within 21 days prior to screening or within 6
             weeks prior to the anticipated first pharmacokinetics(PK) infusion

          -  Participant has an abnormal renal function (serum creatinine &gt; 1.5 mg/dL)

          -  Participant has active hepatic disease (alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) levels &gt;5 times the upper limit of normal)

          -  Participant has severe chronic liver disease as evidenced by, but not limited to, any
             of the following: International Normalized Ratio (INR) &gt; 1.4, hypoalbuminemia, portal
             vein hypertension including presence of otherwise unexplained splenomegaly, and
             history of esophageal varices

          -  Participant has clinical and/or laboratory evidence of abnormal hemostasis from causes
             other than hemophilia A (eg, late-stage chronic liver disease, immune thrombocytopenia
             purpura)

          -  Participant is currently receiving, or is scheduled to receive during the course of
             the clinical study, an immunomodulating drug other than anti-retroviral chemotherapy
             (eg, alfa-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone
             greater than 10 mg/day)

          -  Participant has a known hypersensitivity to mouse or hamster proteins

          -  Participant has participated in another clinical study involving an investigational
             product or investigational device within 30 days prior to enrollment or is scheduled
             to participate in another clinical study involving an investigational product or
             investigational device during the course of this clinical study

          -  Participant is identified by the investigator as being unable or unwilling to
             cooperate with study procedures

          -  Participant is a member of the team conducting this clinical study or is in a
             dependent relationship with one of the study team members. Dependent relationships
             include close relatives (ie, children, partner/spouse, siblings, or parents) as well
             as employees of the investigator or site personnel conducting the clinical study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter Bio Science Investigator</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>195213</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <results_first_submitted>March 31, 2013</results_first_submitted>
  <results_first_submitted_qc>September 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2013</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted in Russia and Bulgaria at 4 clinical sites.</recruitment_details>
      <pre_assignment_details>29 participants were enrolled. Six participants discontinued, (four were screen failures and two were withdrawn before randomization). Therefore 23 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Two 1500 IU Vials Then One 3000 IU Vial</title>
          <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by one 3000 IU potency vial dissolved in 5 mL diluent.</description>
        </group>
        <group group_id="P2">
          <title>One 3000 IU Vial Then Two 1500 IU Vials</title>
          <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants were randomized to receive via intravenous infusion 3000 International Units (IU) Advate using either one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay</title>
        <description>Computed using the linear trapezoidal method.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay</title>
          <description>Computed using the linear trapezoidal method.</description>
          <population>Intent to Treat</population>
          <units>(IU·h)/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1158" spread="335"/>
                    <measurement group_id="O2" value="1264" spread="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>paired t-test done on the Log(AUC 0-48h)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). One-stage Activated Partial Thromboplastin Time (aPTT) Assay</title>
        <description>Computed using the linear trapezoidal method.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). One-stage Activated Partial Thromboplastin Time (aPTT) Assay</title>
          <description>Computed using the linear trapezoidal method.</description>
          <population>Intent to Treat</population>
          <units>(IU·h)/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1129" spread="310"/>
                    <measurement group_id="O2" value="1226" spread="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>paired t-test done on the Log(AUC 0-48h)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). Chromogenic Assay</title>
        <description>The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). Chromogenic Assay</title>
          <description>The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.</description>
          <population>Intent to Treat</population>
          <units>(IU·h)/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1267" spread="395"/>
                    <measurement group_id="O2" value="1383" spread="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). One-stage aPTT Assay</title>
        <description>The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). One-stage aPTT Assay</title>
          <description>The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.</description>
          <population>Intent to Treat</population>
          <units>(IU·h)/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1235" spread="364"/>
                    <measurement group_id="O2" value="1348" spread="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery at Cmax - Chromogenic Assay</title>
        <description>Determined as the highest Factor VIII (FVIII) activity achieved post-infusion</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery at Cmax - Chromogenic Assay</title>
          <description>Determined as the highest Factor VIII (FVIII) activity achieved post-infusion</description>
          <population>Intent to Treat</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.40"/>
                    <measurement group_id="O2" value="2.04" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery at Cmax - One-stage aPTT Assay</title>
        <description>Determined as the highest FVIII activity achieved post-infusion</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery at Cmax - One-stage aPTT Assay</title>
          <description>Determined as the highest FVIII activity achieved post-infusion</description>
          <population>Intent to Treat</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.43"/>
                    <measurement group_id="O2" value="1.96" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery at 30 Minutes- Chromogenic Assay</title>
        <description>Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion</description>
        <time_frame>30 minutes pre-infusion and 30 minutes post-infusion</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery at 30 Minutes- Chromogenic Assay</title>
          <description>Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion</description>
          <population>Intent to Treat</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.42"/>
                    <measurement group_id="O2" value="1.84" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery at 30 Minutes- One-stage aPTT Assay</title>
        <description>Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion</description>
        <time_frame>30 minutes pre-infusion and 30 minutes post-infusion</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery at 30 Minutes- One-stage aPTT Assay</title>
          <description>Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion</description>
          <population>Intent to Treat</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.43"/>
                    <measurement group_id="O2" value="1.90" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Phase Half-life- Chromogenic Assay</title>
        <description>calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Phase Half-life- Chromogenic Assay</title>
          <description>calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.27" spread="4.05"/>
                    <measurement group_id="O2" value="12.84" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Phase Half-life- One-stage aPTT Assay</title>
        <description>calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Phase Half-life- One-stage aPTT Assay</title>
          <description>calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.80" spread="3.95"/>
                    <measurement group_id="O2" value="13.50" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVIII Clearance- Chromogenic Assay</title>
        <description>computed as the dose divided by total AUC</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>FVIII Clearance- Chromogenic Assay</title>
          <description>computed as the dose divided by total AUC</description>
          <population>Intent to Treat</population>
          <units>mL/(kg·h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" spread="1.75"/>
                    <measurement group_id="O2" value="3.99" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVIII Clearance- One-stage aPTT Assay</title>
        <description>Computed as the dose divided by total AUC</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>FVIII Clearance- One-stage aPTT Assay</title>
          <description>Computed as the dose divided by total AUC</description>
          <population>Intent to Treat</population>
          <units>mL/(kg·h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="1.81"/>
                    <measurement group_id="O2" value="4.06" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT)- Chromogenic Assay</title>
        <description>Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT)- Chromogenic Assay</title>
          <description>Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)</description>
          <population>Intent to Treat</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.02" spread="5.37"/>
                    <measurement group_id="O2" value="16.84" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT)- One-stage aPTT Assay</title>
        <description>Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT)- One-stage aPTT Assay</title>
          <description>Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)</description>
          <population>Intent to Treat</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.95" spread="4.77"/>
                    <measurement group_id="O2" value="17.16" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State- Chromogenic Assay</title>
        <description>computed as Clearance (CL) * Mean residence time (MRT)</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State- Chromogenic Assay</title>
          <description>computed as Clearance (CL) * Mean residence time (MRT)</description>
          <population>Intent to Treat</population>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.23"/>
                    <measurement group_id="O2" value="0.61" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State- One-stage aPTT Assay</title>
        <description>computed as CL * MRT</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State- One-stage aPTT Assay</title>
          <description>computed as CL * MRT</description>
          <population>Intent to Treat</population>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.19"/>
                    <measurement group_id="O2" value="0.64" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- Chromogenic Assay</title>
        <description>Determined as the highest FVIII activity achieved post-infusion.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- Chromogenic Assay</title>
          <description>Determined as the highest FVIII activity achieved post-infusion.</description>
          <population>Intent to Treat</population>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="21"/>
                    <measurement group_id="O2" value="101" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- One-stage aPTT Assay</title>
        <description>Determined as the highest FVIII activity achieved post-infusion.</description>
        <time_frame>Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>One 3000 International Unit (IU) Vial</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using one 3000 IU potency vial dissolved in 5 mL diluent</description>
          </group>
          <group group_id="O2">
            <title>Two 1500 IU Vials</title>
            <description>Participants received via intravenous (IV) infusion 3000 International Units (IU) Advate using two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total)</description>
          </group>
        </group_list>
        <measure>
          <title>Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- One-stage aPTT Assay</title>
          <description>Determined as the highest FVIII activity achieved post-infusion.</description>
          <population>Intent to Treat</population>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="21"/>
                    <measurement group_id="O2" value="98" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period, approximately 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>One 3000 International Unit (IU) Vial</title>
        </group>
        <group group_id="E2">
          <title>Two 1500 IU Vials</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication of the main/primary endpoint or ≤24 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) prior to submission for publication, and shall review and if necessary amend the manuscript in ≤30 days</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigitt Abbuehl, MD, Medical Director, Hematology/Hemophilia</name_or_title>
      <organization>Baxter</organization>
      <email>brigitt_abbuehl@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

